There is no wrong end point. Fvc is the correct end point. What i use everyday to take care of pf pts. As long as distance walked. Mortality is not the end point. This is a fatak dz with lots of variability. Most pts live for 20 yrs or more. Hard to do a study with that as endpoint. Drug wiol be approved. It is safe and effective in slowing dz progress.
Read the FDA review. The agency told InterMune that survival was to be the registration end-point. InterMune chose to use a softer endpoint. The softer endpoint was not met in two independent trials. The NDA failed. End of story.
ha ha you idiot, what else are you going to use to monitor your patients - death?? You are a moron - if you really are a doctor. What you use to monitor your patients is completely irrelevant to what should be used to judge efficacy.